RN-564

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameRN-564
Drug Alias NameHumanized anti-Dkk-1 mAb (Pfizer)Humanized anti-Dickkopf-1 monoclonal antibody (Pfizer)PF-4840082PF-04840082RN-564
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionDickkopf-related protein 1 inhibitors
TargetsDickkopf-related protein 1
Therapy Area/IndicationsOsteoporosisBone Diseases, MetabolicBone Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsOsteoporosisBone Diseases, MetabolicBone Diseases

Other Information

ATC CodeN/A
Related LinksN/A